A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)

NCT03606460 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

141

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Ocrelizumab Dose 1
DRUG: Ocrelizumab Dose 2 and Dose 3

Sponsor

Genentech, Inc.